APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Schistosomiasis

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Schistosomiasis Market Outlook and Growth Opportunities 2026

Report ID 173986480425 December 2025194 pages

Choose your research edition.

Industry ResearchDrugs for Schistosomiasis Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Schistosomiasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Drugs for Schistosomiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Schistosomiasis Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Schistosomiasis Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.

East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,

Read the full market overview

Followed by West Africa(20%).

This report provides an overview of the global Drugs for Schistosomiasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Schistosomiasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Schistosomiasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Schistosomiasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Schistosomiasis Segment by Company

Shin Poong

Merck

Bayer

EIPICO

Chandra Bhagat Pharma

Taj Pharmaceuticals

Drugs for Schistosomiasis Segment by Type

Praziquantel

Oxamniquine

Other

Drugs for Schistosomiasis Segment by Application

S. haematobium

S. mansoni

S. japonicum

S. mekongi

S. intercalatum

Drugs for Schistosomiasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Schistosomiasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Schistosomiasis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Schistosomiasis significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Schistosomiasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Schistosomiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Schistosomiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Schistosomiasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Schistosomiasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Schistosomiasis industry.

Chapter 3: Detailed analysis of Drugs for Schistosomiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Schistosomiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Schistosomiasis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Schistosomiasis Industry Trends Table 2. Drugs for Schistosomiasis Industry Drivers Table 3. Drugs for Schistosomiasis Industry Opportunities and Challenges Table 4. Drugs for Schistosomiasis Industry Restraints Table 5. Global Drugs for Schistosomiasis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Schistosomiasis Revenue Share by Company (2021-2026) Table 7. Global Drugs for Schistosomiasis Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Drugs for Schistosomiasis Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Schistosomiasis Average Price (USD/K Units) of Company (2021-2026) Table 10. Global Drugs for Schistosomiasis Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Schistosomiasis Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Schistosomiasis Company, Product Type & Application Table 13. Global Drugs for Schistosomiasis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Schistosomiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Praziquantel Table 18. Significant Companies of Oxamniquine Table 19. Significant Companies of Other Table 20. Global Drugs for Schistosomiasis Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 21. Global Drugs for Schistosomiasis Sales Volume by Type (2021-2026) & (M Units) Table 22. Global Drugs for Schistosomiasis Sales Volume by Type (2027-2032) & (M Units) Table 23. Global Drugs for Schistosomiasis Sales Volume Share by Type (2021-2026) Table 24. Global Drugs for Schistosomiasis Sales Volume Share by Type (2027-2032) Table 25. Global Drugs for Schistosomiasis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Schistosomiasis Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Schistosomiasis Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Schistosomiasis Sales Value Share by Type (2021-2026) Table 29. Global Drugs for Schistosomiasis Sales Value Share by Type (2027-2032) Table 30. Significant Companies of S. haematobium Table 31. Significant Companies of S. mansoni Table 32. Significant Companies of S. japonicum Table 33. Significant Companies of S. mekongi Table 34. Significant Companies of S. intercalatum Table 35. Global Drugs for Schistosomiasis Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 36. Global Drugs for Schistosomiasis Sales Volume by Application (2021-2026) & (M Units) Table 37. Global Drugs for Schistosomiasis Sales Volume by Application (2027-2032) & (M Units) Table 38. Global Drugs for Schistosomiasis Sales Volume Share by Application (2021-2026) Table 39. Global Drugs for Schistosomiasis Sales Volume Share by Application (2027-2032) Table 40. Global Drugs for Schistosomiasis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Drugs for Schistosomiasis Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Drugs for Schistosomiasis Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Drugs for Schistosomiasis Sales Value Share by Application (2021-2026) Table 44. Global Drugs for Schistosomiasis Sales Value Share by Application (2027-2032) Table 45. Global Drugs for Schistosomiasis Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 46. Global Drugs for Schistosomiasis Sales by Region (2021-2026) & (M Units) Table 47. Global Drugs for Schistosomiasis Sales Market Share by Region (2021-2026) Table 48. Global Drugs for Schistosomiasis Sales by Region (2027-2032) & (M Units) Table 49. Global Drugs for Schistosomiasis Sales Market Share by Region (2027-2032) Table 50. Global Drugs for Schistosomiasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Drugs for Schistosomiasis Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Drugs for Schistosomiasis Sales Value Share by Region (2021-2026) Table 53. Global Drugs for Schistosomiasis Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Drugs for Schistosomiasis Sales Value Share by Region (2027-2032) Table 55. Global Drugs for Schistosomiasis Market Average Price (USD/K Units) by Region (2021-2026) Table 56. Global Drugs for Schistosomiasis Market Average Price (USD/K Units) by Region (2027-2032) Table 57. Global Drugs for Schistosomiasis Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 58. Global Drugs for Schistosomiasis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Drugs for Schistosomiasis Sales by Country (2021-2026) & (M Units) Table 60. Global Drugs for Schistosomiasis Sales Market Share by Country (2021-2026) Table 61. Global Drugs for Schistosomiasis Sales by Country (2027-2032) & (M Units) Table 62. Global Drugs for Schistosomiasis Sales Market Share by Country (2027-2032) Table 63. Global Drugs for Schistosomiasis Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Drugs for Schistosomiasis Sales Value Market Share by Country (2021-2026) Table 65. Global Drugs for Schistosomiasis Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Drugs for Schistosomiasis Sales Value Market Share by Country (2027-2032) Table 67. Shin Poong Company Information Table 68. Shin Poong Business Overview Table 69. Shin Poong Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 70. Shin Poong Drugs for Schistosomiasis Product Portfolio Table 71. Shin Poong Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 75. Merck Drugs for Schistosomiasis Product Portfolio Table 76. Merck Recent Development Table 77. Bayer Company Information Table 78. Bayer Business Overview Table 79. Bayer Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 80. Bayer Drugs for Schistosomiasis Product Portfolio Table 81. Bayer Recent Development Table 82. EIPICO Company Information Table 83. EIPICO Business Overview Table 84. EIPICO Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 85. EIPICO Drugs for Schistosomiasis Product Portfolio Table 86. EIPICO Recent Development Table 87. Chandra Bhagat Pharma Company Information Table 88. Chandra Bhagat Pharma Business Overview Table 89. Chandra Bhagat Pharma Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 90. Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio Table 91. Chandra Bhagat Pharma Recent Development Table 92. Taj Pharmaceuticals Company Information Table 93. Taj Pharmaceuticals Business Overview Table 94. Taj Pharmaceuticals Drugs for Schistosomiasis Sales (M Units), Value (US$ Million), Price (USD/K Units) and Gross Margin (2021-2026) Table 95. Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio Table 96. Taj Pharmaceuticals Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Drugs for Schistosomiasis Distributors List Table 100. Drugs for Schistosomiasis Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Drugs for Schistosomiasis Product Image Figure 2. Global Drugs for Schistosomiasis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Schistosomiasis Sales (2021-2032) & (M Units) Figure 5. Global Drugs for Schistosomiasis Sales Average Price (USD/K Units) & (2021-2032) Figure 6. Global Drugs for Schistosomiasis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Praziquantel Image Figure 10. Oxamniquine Image Figure 11. Other Image Figure 12. Global Drugs for Schistosomiasis Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 13. Global Drugs for Schistosomiasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Schistosomiasis Sales Volume Share by Type (2021-2032) Figure 15. Global Drugs for Schistosomiasis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Schistosomiasis Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Schistosomiasis Sales Value Share by Type (2021-2032) Figure 18. S. haematobium Image Figure 19. S. mansoni Image Figure 20. S. japonicum Image Figure 21. S. mekongi Image Figure 22. S. intercalatum Image Figure 23. Global Drugs for Schistosomiasis Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 24. Global Drugs for Schistosomiasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs for Schistosomiasis Sales Volume Share by Application (2021-2032) Figure 26. Global Drugs for Schistosomiasis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Drugs for Schistosomiasis Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Drugs for Schistosomiasis Sales Value Share by Application (2021-2032) Figure 29. Global Drugs for Schistosomiasis Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 30. Global Drugs for Schistosomiasis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Drugs for Schistosomiasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Drugs for Schistosomiasis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 34. North America Drugs for Schistosomiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Drugs for Schistosomiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Drugs for Schistosomiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 40. South America Drugs for Schistosomiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Drugs for Schistosomiasis Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Drugs for Schistosomiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Drugs for Schistosomiasis Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Drugs for Schistosomiasis Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Praziquantel
  • Oxamniquine
  • Other
Applications
  • S. haematobium
  • S. mansoni
  • S. japonicum
  • S. mekongi
  • S. intercalatum
Companies covered
  • Shin Poong
  • Merck
  • Bayer
  • EIPICO
  • Chandra Bhagat Pharma
  • Taj Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Schistosomiasis Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Schistosomiasis Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Schistosomiasis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Schistosomiasis Market Dynamics
  1. 2.1 Drugs for Schistosomiasis Industry Trends
  2. 2.2 Drugs for Schistosomiasis Industry Drivers
  3. 2.3 Drugs for Schistosomiasis Industry Opportunities and Challenges
  4. 2.4 Drugs for Schistosomiasis Industry Restraints
3 Drugs for Schistosomiasis Market by Company
  1. 3.1 Global Drugs for Schistosomiasis Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Schistosomiasis Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Schistosomiasis Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Schistosomiasis Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Schistosomiasis Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Schistosomiasis Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Schistosomiasis Company Product Type and Application
  8. 3.8 Global Drugs for Schistosomiasis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Schistosomiasis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Schistosomiasis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Schistosomiasis Market by Type
  1. 4.1 Drugs for Schistosomiasis Type Introduction
  2. 4.1.1 Praziquantel
  3. 4.1.2 Oxamniquine
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Schistosomiasis Sales Volume by Type
  6. 4.2.1 Global Drugs for Schistosomiasis Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Schistosomiasis Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Drugs for Schistosomiasis Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Drugs for Schistosomiasis Sales Value by Type
  10. 4.3.1 Global Drugs for Schistosomiasis Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Schistosomiasis Sales Value by Type (2021-2032)
  12. 4.3.3 Global Drugs for Schistosomiasis Sales Value Share by Type (2021-2032)
5 Drugs for Schistosomiasis Market by Application
  1. 5.1 Drugs for Schistosomiasis Application Introduction
  2. 5.1.1 S. haematobium
  3. 5.1.2 S. mansoni
  4. 5.1.3 S. japonicum
  5. 5.1.4 S. mekongi
  6. 5.1.5 S. intercalatum
  7. 5.2 Global Drugs for Schistosomiasis Sales Volume by Application
  8. 5.2.1 Global Drugs for Schistosomiasis Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Drugs for Schistosomiasis Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Drugs for Schistosomiasis Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Drugs for Schistosomiasis Sales Value by Application
  12. 5.3.1 Global Drugs for Schistosomiasis Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Drugs for Schistosomiasis Sales Value by Application (2021-2032)
  14. 5.3.3 Global Drugs for Schistosomiasis Sales Value Share by Application (2021-2032)
6 Drugs for Schistosomiasis Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Schistosomiasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Schistosomiasis Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Schistosomiasis Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Schistosomiasis Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Schistosomiasis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Schistosomiasis Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Schistosomiasis Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Schistosomiasis Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Schistosomiasis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Schistosomiasis Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Schistosomiasis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Schistosomiasis Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Schistosomiasis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Schistosomiasis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Schistosomiasis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Schistosomiasis Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Schistosomiasis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Schistosomiasis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Schistosomiasis Sales Value Share by Country, 2025 VS 2032
7 Drugs for Schistosomiasis Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Schistosomiasis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Schistosomiasis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Schistosomiasis Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Schistosomiasis Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Schistosomiasis Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Schistosomiasis Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Schistosomiasis Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Schistosomiasis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Schistosomiasis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Schistosomiasis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Schistosomiasis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shin Poong
  2. 8.1.1 Shin Poong Company Information
  3. 8.1.2 Shin Poong Business Overview
  4. 8.1.3 Shin Poong Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shin Poong Drugs for Schistosomiasis Product Portfolio
  6. 8.1.5 Shin Poong Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Drugs for Schistosomiasis Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Drugs for Schistosomiasis Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 EIPICO
  20. 8.4.1 EIPICO Company Information
  21. 8.4.2 EIPICO Business Overview
  22. 8.4.3 EIPICO Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 EIPICO Drugs for Schistosomiasis Product Portfolio
  24. 8.4.5 EIPICO Recent Developments
  25. 8.5 Chandra Bhagat Pharma
  26. 8.5.1 Chandra Bhagat Pharma Company Information
  27. 8.5.2 Chandra Bhagat Pharma Business Overview
  28. 8.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio
  30. 8.5.5 Chandra Bhagat Pharma Recent Developments
  31. 8.6 Taj Pharmaceuticals
  32. 8.6.1 Taj Pharmaceuticals Company Information
  33. 8.6.2 Taj Pharmaceuticals Business Overview
  34. 8.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio
  36. 8.6.5 Taj Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Schistosomiasis Value Chain Analysis
  2. 9.1.1 Drugs for Schistosomiasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Schistosomiasis Sales Mode & Process
  6. 9.2 Drugs for Schistosomiasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Schistosomiasis Distributors
  9. 9.2.3 Drugs for Schistosomiasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst